Details for New Drug Application (NDA): 209888

NDA 209888 describes ETODOLAC, which is a drug marketed by Ani Pharms, Apotex, Biopharm, Chartwell Molecules, Ipca Labs Ltd, Mylan, Natco Pharma, Sandoz, Taro, Actavis Elizabeth, Bayshore Pharms Llc, Teva, Watson Labs Florida, Zydus Pharms, Amneal Pharms Co, Apotex Inc, Edenbridge Pharms, Ivax Sub Teva Pharms, Oxford Pharms, Pangea, Ranbaxy Labs Ltd, Shree Hari Intl, Taro Pharm Inds, and Watson Labs, and is included in thirty-nine NDAs. It is available from thirty-one suppliers. Additional details are available on the ETODOLAC profile page.

The generic ingredient in ETODOLAC is etodolac. There are twenty-three drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the etodolac profile page.

Summary for 209888

Tradename:	ETODOLAC
Applicant:	Edenbridge Pharms
Ingredient:	etodolac
Patents:	0

Pharmacology for NDA: 209888

Mechanism of Action

Cyclooxygenase Inhibitors

Medical Subject Heading (MeSH) Categories for 209888

Cyclooxygenase 2 Inhibitors

Suppliers and Packaging for NDA: 209888

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ETODOLAC	etodolac	TABLET;ORAL	209888	ANDA	Edenbridge Pharmaceuticals LLC.	42799-111	42799-111-01	100 TABLET, FILM COATED in 1 BOTTLE (42799-111-01)
ETODOLAC	etodolac	TABLET;ORAL	209888	ANDA	Edenbridge Pharmaceuticals LLC.	42799-112	42799-112-01	100 TABLET, FILM COATED in 1 BOTTLE (42799-112-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	400MG
Approval Date:	Nov 30, 2018	TE:	AB	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	500MG
Approval Date:	Nov 30, 2018	TE:	AB	RLD:	No

Complete Access Available with Subscription